{"id":877,"date":"2019-04-03T23:35:41","date_gmt":"2019-04-03T23:35:41","guid":{"rendered":"https:\/\/sfj-pharma.com\/?p=877"},"modified":"2021-02-10T18:34:31","modified_gmt":"2021-02-10T18:34:31","slug":"vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu","status":"publish","type":"post","link":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/","title":{"rendered":"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU)"},"content":{"rendered":"\n<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO\u00ae (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.<\/p>\n\n\n\n<p>\u201cLung cancer remains the leading cause of cancer-related death worldwide and despite advances in biomarker-driven therapies, overcoming resistance continues to be crucial in treating EGFR-mutated non-small cell lung cancer,\u201d said Andreas Penk, M.D., regional president, Oncology International Developed Markets at Pfizer. \u201cThe marketing authorization of VIZIMPRO, which has shown a more than five-month improvement in progression-free survival over an existing therapy in a Phase 3 clinical trial, provides a new option for patients with EGFR-mutated non-small cell lung cancer and reinforces Pfizer\u2019s ongoing commitment to addressing the remaining needs of the thousands of EU patients with this disease.\u201d<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><a href=\"https:\/\/sfj-pharma.com\/wp-content\/uploads\/2019\/04\/VIZIMPRO.pdf\">Read Full Press Release<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO\u00ae (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor&#8230;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[103],"tags":[],"class_list":["post-877","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) - SFJ Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) - SFJ Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"NEW YORK&#8211;(BUSINESS WIRE)&#8211;Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO\u00ae (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\" \/>\n<meta property=\"og:site_name\" content=\"SFJ Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-03T23:35:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-10T18:34:31+00:00\" \/>\n<meta name=\"author\" content=\"khateam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"khateam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\"},\"author\":{\"name\":\"khateam\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\"},\"headline\":\"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU)\",\"datePublished\":\"2019-04-03T23:35:41+00:00\",\"dateModified\":\"2021-02-10T18:34:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\"},\"wordCount\":162,\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\",\"url\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\",\"name\":\"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) - SFJ Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\"},\"datePublished\":\"2019-04-03T23:35:41+00:00\",\"dateModified\":\"2021-02-10T18:34:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sfj-pharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"name\":\"SFJ Pharmaceuticals\",\"description\":\"Resources for Accelerated Clinical Development\",\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sfj-pharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\",\"name\":\"SFJ Pharmaceuticals\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"contentUrl\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"width\":750,\"height\":205,\"caption\":\"SFJ Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\",\"name\":\"khateam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"caption\":\"khateam\"},\"sameAs\":[\"https:\/\/sfj-pharma.com\"],\"url\":\"https:\/\/www.sfj-pharma.com\/author\/khateam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) - SFJ Pharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/","og_locale":"en_US","og_type":"article","og_title":"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) - SFJ Pharmaceuticals","og_description":"NEW YORK&#8211;(BUSINESS WIRE)&#8211;Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO\u00ae (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor...","og_url":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/","og_site_name":"SFJ Pharmaceuticals","article_published_time":"2019-04-03T23:35:41+00:00","article_modified_time":"2021-02-10T18:34:31+00:00","author":"khateam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"khateam","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/#article","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/"},"author":{"name":"khateam","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc"},"headline":"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU)","datePublished":"2019-04-03T23:35:41+00:00","dateModified":"2021-02-10T18:34:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/"},"wordCount":162,"publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/","url":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/","name":"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) - SFJ Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/#website"},"datePublished":"2019-04-03T23:35:41+00:00","dateModified":"2021-02-10T18:34:31+00:00","breadcrumb":{"@id":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sfj-pharma.com\/vizimpro-dacomitinib-receives-marketing-authorization-in-european-union-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sfj-pharma.com\/"},{"@type":"ListItem","position":2,"name":"VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU)"}]},{"@type":"WebSite","@id":"https:\/\/www.sfj-pharma.com\/#website","url":"https:\/\/www.sfj-pharma.com\/","name":"SFJ Pharmaceuticals","description":"Resources for Accelerated Clinical Development","publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sfj-pharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sfj-pharma.com\/#organization","name":"SFJ Pharmaceuticals","url":"https:\/\/www.sfj-pharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","contentUrl":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","width":750,"height":205,"caption":"SFJ Pharmaceuticals"},"image":{"@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc","name":"khateam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","caption":"khateam"},"sameAs":["https:\/\/sfj-pharma.com"],"url":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"}]}},"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"khateam","author_link":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.sfj-pharma.com\/category\/news\/\" rel=\"category tag\">News<\/a>","rttpg_excerpt":"NEW YORK&#8211;(BUSINESS WIRE)&#8211;Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO\u00ae (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor...","_links":{"self":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/comments?post=877"}],"version-history":[{"count":1,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/877\/revisions"}],"predecessor-version":[{"id":7063,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/877\/revisions\/7063"}],"wp:attachment":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/media?parent=877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/categories?post=877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/tags?post=877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}